Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- Overall Response Rate (ORR).
Secondary Objectives:
- The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients
and in the responders.
- Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses
(PR).
- Time to next anticancer therapy (TTNT).